The CE approval opens Europe for Cornerstone Robotics as the company expands its global surgical robotics business
Updated
May 29, 2026 4:20 AM
A tray of surgical tools. PHOTO: UNSPLASH
As surgical robotics companies expand beyond domestic markets, regulatory approvals are becoming a critical part of global growth. Companies are no longer competing only on hardware and clinical performance. They are also competing on their ability to enter tightly regulated healthcare systems and build long-term hospital partnerships.
Hong Kong-based Cornerstone Robotics is now moving further into that phase of expansion after its Sentire Endoscopic Surgical System received CE Mark certification under the European Union’s Medical Device Regulation framework.
The approval allows the company to commercialize the system across European markets for minimally invasive procedures in general surgery, gynecology, thoracic surgery and urology. For surgical robotics companies, regulatory approvals often represent more than product validation. They also determine market access, hospital adoption opportunities and long-term commercial scale.
Cornerstone Robotics has already been building clinical operations in the UK ahead of the approval. Since 2025, the company has worked with Portsmouth Hospitals University NHS Trust on clinical investigations involving the Sentire Surgical System. According to the company, the system has been used across procedures involving urology, gynecology and gastrointestinal surgery. The company says the clinical investigation helped generate real-world data to support physician training, research and future adoption efforts.
Alongside the regulatory approval, Cornerstone Robotics is also expanding its local operations in Europe. The company established a UK subsidiary in 2025 and has been developing training, clinical support and after-sales service capabilities for hospitals using the system.
That operational buildout reflects a larger challenge inside surgical robotics. Hospitals adopting robotic systems often require ongoing clinical training, technical support and workflow integration alongside the hardware itself.
Cornerstone Robotics says its strategy centers around vertically integrated development across engineering, software, imaging and robotics systems. The company argues that this structure gives it greater control over product development, supply chain management and long-term operational stability.
Professor Samuel Au, Founder and CEO of Cornerstone Robotics, said: "Receiving CE Certification marks a major milestone in Cornerstone Robotics' evolution from a technology innovator to a global clinical solutions provider. From our first clinical investigation in Portsmouth, UK, to achieving European regulatory approval, each step of the journey reflects our commitment to proprietary innovation, product excellence, and clinical value. Looking ahead, we will continue expanding into key global markets and partnering with leading medical institutions to bring high-quality surgical robotic solutions to more physicians and patients worldwide."
The CE approval also comes several months after the company completed an oversubscribed financing round of approximately US$200 million in November 2025.
The funding and regulatory expansion together signal how surgical robotics companies are increasingly entering a more commercially focused stage of growth. Beyond research and development, companies are now investing more heavily in regulatory approvals, hospital partnerships, physician training and international operational infrastructure as competition expands across global healthcare markets.
Keep Reading
Examining the shift from fast answers to verified intelligence in enterprise AI.
Updated
January 8, 2026 6:33 PM
Startup employee reviewing business metrics on an AI-powered dashboard. PHOTO: FREEPIK
Neuron7.ai, a company that builds AI systems to help service teams resolve technical issues faster, has launched Neuro. It is a new kind of AI agent built for environments where accuracy matters more than speed. From manufacturing floors to hospital equipment rooms, Neuro is designed for situations where a wrong answer can halt operations.
What sets Neuro apart is its focus on reliability. Instead of relying solely on large language models that often produce confident but inaccurate responses, Neuro combines deterministic AI — which draws on verified, trusted data — with autonomous reasoning for more complex cases. This hybrid design helps the system provide context-aware resolutions without inventing answers or “hallucinating”, a common issue that has made many enterprises cautious about adopting agentic AI.
“Enterprise adoption of agentic AI has stalled despite massive vendor investment. Gartner predicts 40% of projects will be canceled by 2027 due to reliability concerns”, said Niken Patel, CEO and Co-Founder of Neuron7. “The root cause is hallucinations. In service operations, outcomes are binary. An issue is either resolved or it is not. Probabilistic AI that is right only 70% of the time fails 30% of your customers and that failure rate is unacceptable for mission-critical service”.
That concern shaped how Neuro was built. “We use deterministic guided fixes for known issues. No guessing, no hallucinations — and reserve autonomous AI reasoning for complex scenarios. What sets Neuro apart is knowing which mode to use. While competitors race to make agents more autonomous, we're focused on making service resolution more accurate and trusted”, Patel explained.
At the heart of Neuro is the Smart Resolution Hub, Neuron7’s central intelligence layer that consolidates service data, knowledge bases and troubleshooting workflows into one conversational experience. This means a technician can describe a problem — say, a diagnostic error in an MRI scanner — and Neuro can instantly generate a verified, step-by-step solution. If the problem hasn’t been encountered before, it can autonomously scan through thousands of internal and external data points to identify the most likely fix, all while maintaining traceability and compliance.
Neuro’s architecture also makes it practical for real-world use. It integrates seamlessly with enterprise systems such as Salesforce, Microsoft, ServiceNow and SAP, allowing companies to embed it within their existing support operations. Early users of Neuron7’s platform have reported measurable improvements — faster resolutions, higher customer satisfaction and reduced downtime — thanks to guided intelligence that scales expert-level problem solving across teams.
The timing of Neuro’s debut feels deliberate. As organizations look to move past the hype of generative AI, trust and accountability have become the new benchmarks. AI systems that can explain their reasoning and stay within verifiable boundaries are emerging as the next phase of enterprise adoption.
“The market has figured out how to build autonomous agents”, Patel said. “The unsolved problem is building accurate agents for contexts where errors have consequences. Neuro fills that gap”.
Neuron7 is building a system that knows its limits — one that reasons carefully, acts responsibly and earns trust where it matters most. In a space dominated by speculation, that discipline may well redefine what “intelligent” really means in enterprise AI.